GlycoMimetics Files 8-K on Material Agreement; Details Pending

TL;DR

**GlycoMimetics signed a material agreement, but the 8-K is light on details, leaving investors in the dark.**

AI Summary

GlycoMimetics, Inc. filed an 8-K on January 2, 2024, to report an "Entry into a Material Definitive Agreement." While the filing confirms the event date and the company's details, it does not disclose the specifics of the agreement itself. This matters to investors because without the details of the material agreement, it's impossible to assess its potential impact on the company's financial health, future prospects, or stock valuation, leaving a significant information gap.

Why It Matters

This filing indicates a significant business event for GlycoMimetics, Inc. but withholds crucial details, making it impossible for investors to evaluate the financial implications or strategic direction.

Risk Assessment

Risk Level: medium — The lack of specific details about a 'material definitive agreement' introduces uncertainty and risk for investors, as the nature of the agreement could be either positive or negative.

Analyst Insight

Investors should await further disclosures from GlycoMimetics regarding the specifics of the 'Material Definitive Agreement' before making any investment decisions, as the current filing lacks the necessary information to assess impact.

Key Players & Entities

• GlycoMimetics, Inc. (company) — the registrant filing the 8-K
• January 2, 2024 (date) — date of the earliest event reported and filing date
• 001-36177 (other) — Commission File Number for GlycoMimetics, Inc.
• GLYC (other) — Trading Symbol for GlycoMimetics, Inc. Common Stock
• The Nasdaq Stock Market LLC (other) — exchange where GlycoMimetics, Inc. Common Stock is registered

Forward-Looking Statements

• GlycoMimetics will file an amendment or a subsequent 8-K with the full details of the material definitive agreement. (GlycoMimetics, Inc.) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value GLYC The Nasdaq Stock Mar

Filing Documents

• glyc-20240102x8k.htm (8-K) — 39KB
• 0001558370-24-000013.txt ( ) — 154KB
• glyc-20240102.xsd (EX-101.SCH) — 3KB
• glyc-20240102_lab.xml (EX-101.LAB) — 15KB
• glyc-20240102_pre.xml (EX-101.PRE) — 10KB
• glyc-20240102x8k_htm.xml (XML) — 5KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On January 2, 2024, GlycoMimetics, Inc. (the " Company ") entered into a project agreement (the " Project Agreement ") with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (" Patheon "), pursuant to which Patheon will manufacture and supply the Company with its drug candidate, uproleselan, for commercial sale should the Company receive marketing approval from the U.S. Food and Drug Administration. The Project Agreement is subject to the additional terms of a Master Services Agreement previously entered into by the Company and Patheon that governs the general terms under which Patheon will provide non-exclusive manufacturing and commercial services to the Company from time to time. Pursuant to the Project Agreement, Patheon will manufacture commercial supplies of injectable uproleselan from active pharmaceutical ingredient supplied by the Company. Patheon will be responsible for supplying the other required raw materials and packaging components and will also provide supportive manufacturing services such as quality control testing for raw materials, packaging components and finished product. Under the Project Agreement, the Company has provided Patheon with its forecast of required annual volumes through 2027. The Project Agreement has an initial term through December 31, 2026 and will automatically renew for additional three-year periods unless earlier terminated. After the initial term, either party may terminate the Project Agreement by giving 18 months' written notice for any business reason. Either party may terminate the Project Agreement within a given time period upon any material breach that is left uncured by the other party. Upon completion, expiration and/or termination of the Project Agreement, the Company will pay Patheon for all service rendered, all costs and expenses incurred and any termination fees. The foregoing description of the Project Agreement does not purpor

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLYCOMIMETICS, INC. By: /s/ Brian M. Hahn Date: January 2, 2024 Brian M. Hahn Chief Financial Officer and Senior Vice President 3

View Full Filing

View this 8-K filing on SEC EDGAR